摘要
银屑病是一种常见并易复发的慢性炎症性皮肤病。本病的确切病因尚未清楚,Th1和Th17介导的慢性炎症反应、表皮过度增殖和慢性新血管生成是目前被广泛认可的发病机制,阻断TNF-α和IL-23/Th17相关途径的生物制剂是迄今为止治疗银屑病最有效的药物。然而,尽管生物制剂治疗方面取得了较好的进展,但仍无法完全满足银屑病治疗上的需要,提示目前对银屑病潜在发病机制仍存在认识上的盲点。因此,本综述主要关注包括Th17细胞及其他参与银屑病发病机制的重要效应细胞(中性粒细胞、单核细胞和肥大细胞)以及相关细胞因子的研究进展,以便更全面了解银屑病的发病机制,为银屑病的治疗提供理论依据。
Psoriasis is a common and recurrent chronic inflammatory skin disease.The exact etiology of this disease is not clear.Th1 and Th17 mediated chronic inflammatory response,epidermal hyperproliferation and chronic neovascularization are widely recognized pathogenesis.Biological agents blocking TNF-αand IL-23/Th17 related pathways are the most effective drugs to treat psoriasis so far.However,despite the good progress in biological agent therapy,it still can not fully meet the needs of psoriasis treatment,suggesting that there is still a blind spot in understanding the potential pathogenesis of psoriasis.Therefore,this review mainly focuses on the research progress of Th17 cells and other important effector cells(neutrophils,monocytes and mast cells)and related cytokines involved in the pathogenesis of psoriasis,so as to understand the pathogenesis of psoriasis more comprehensively and provide theoretical basis for the treatment of psoriasis.
作者
陈雪琴
宋志强
CHEN Xueqin;SONG Zhiqiang(Department of Dermatology,First Hospital Affiliated to Army Military Medical University,Southwest Hospital,Chongqing 400038,China)
出处
《中国皮肤性病学杂志》
CAS
CSCD
北大核心
2020年第11期1321-1325,共5页
The Chinese Journal of Dermatovenereology
基金
陆军军医大学西南医院创新团队培养计划(SWH2018TD-02)。
作者简介
通信作者:宋志强,E-mail:zhiqiang.song@hotmail.com。
